Peptides displayed by HLA for use in immunotherapy against different types of cancers
Inventors
Hannen, Ricarda • Hukelmann, Jens • Koehler, Florian • Kowalewski, Daniel Johannes • Schuster, Heiko • Schoor, Oliver • Roemer, Michael • Tsou, Chih-Chiang • FRITSCHE, Jens
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12257269-B2
Publication Date
2025-03-25
Expiration Date
Abstract
The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
Core Innovation
The document describes an ALGPMAFRV peptide (SEQ ID NO: 113) provided in the form of a pharmaceutically acceptable salt. The ALGPMAFRV peptide is presented as a target antigen peptide that can be recognized in an immune context.
The document further describes therapeutic use involving activated T cells that kill cancer cells presenting the ALGPMAFRV (SEQ ID NO: 113) peptide. The killing is defined in relation to a peptide presented by cancer cell surfaces, including recognition of the peptide in association with MHC class I.
In addition to the peptide and activated T cell approach, the document describes cancer treatment by administering an adjuvant in combination with the activated T cells. The adjuvant is selected from a specified list of agents including cytokines, and the document also identifies IL-2 as a further specific adjuvant.
Claims Coverage
The partial claim set includes three independent claims: one directed to the ALGPMAFRV peptide in salt form, a second directed to the ALGPMAFRV peptide in salt form, and a third directed to treating cancer using activated T cells that kill cancer cells presenting the ALGPMAFRV peptide. Across these independent claims, the inventive features focus on the defined peptide sequence, providing it as a salt, and cancer treatment using activated T cells recognizing the peptide when presented on MHC class I, with optional adjuvant selection in dependent claims.
Defined ALGPMAFRV peptide as pharmaceutically acceptable salt
A peptide consisting of the amino acid sequence ALGPMAFRV (SEQ ID NO: 113) in the form of a pharmaceutically acceptable salt.
Defined ALGPMAFRV peptide as salt
A peptide consisting of the amino acid sequence ALGPMAFRV (SEQ ID NO: 113) in the form of a salt.
Activated T cells targeting cancer cells presenting ALGPMAFRV via MHC class I
A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of ALGPMAFRV (SEQ ID NO: 113).
Overall, the claim coverage centers on the ALGPMAFRV (SEQ ID NO: 113) peptide defined by sequence and salt form, and on treating a defined set of cancers through administration of activated T cells that kill cancer cells presenting that peptide, with dependent claims further defining peptide recognition in the context of MHC class I and adding adjuvants selected from an enumerated set (including IL-2).
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treatment of a patient who has cancer, where cancer is selected from the group consisting of acute myeloid leukemia, breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gallbladder cancer, glioblastoma, gastric cancer, gastro-esophageal junction cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, small cell lung cancer, urinary bladder carcinoma, and uterine endometrial cancer.
Interested in licensing this patent?